Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGA006
- Development stage
- Preclinical
- Lead developer
- Biogenera
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BGA006 is a peptide nucleic acid (PNA) anti-gene oligonucleotide developed by Biogenera for the treatment of ALK-driven cancers. Utilizing the company's proprietary Ag-PNA technology platform, BGA006 is designed to bind directly to the genomic DNA sequence of the Anaplastic Lymphoma Kinase (ALK) gene. This binding inhibits the transcription of the gene, thereby preventing the synthesis of the ALK protein. This "anti-gene" mechanism of action distinguishes it from traditional antisense oligonucleotides that target mRNA. BGA006 is currently in the preclinical stage of development, with potential applications in various oncology indications where ALK mutations or translocations are present, such as non-small cell lung cancer and certain lymphomas.
- Other names
- ALK-PNA anti-gene oligonucleotideAg-PNAPNA anti-gene oligonucleotide
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)
Beyond the preview
Go deeper on BGA006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGA006.